There are four FDA-approved oral GLP-1 medications in the United States right now, and they contain only two different drugs:
What no drug-name list tells you is that these four pills split into two completely different daily routines. Three are semaglutide, a peptide, and they demand an empty stomach, four ounces of plain water and a thirty-minute wait every morning. The fourth is orforglipron, a small molecule, and its label says take it with or without food. That difference will shape your mornings far more than the milligram numbers will.
Rybelsus and Ozempic tablets carry the same two indications: improving glycemic control in adults with type 2 diabetes, and reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for them. They are the same molecule in the same tablet form under two brand names, and the prescribing information states directly that they are not substitutable on a mg-to-mg basis. Rybelsus tops out at 14 mg and Ozempic tablets at 9 mg, so the smaller-sounding number is not a smaller dose.
Wegovy tablets are the weight-management semaglutide pill, approved both to reduce and maintain body weight and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. The recommended maintenance dose is 25 mg once daily, a number that exists in no other semaglutide product.
Foundayo is the only oral GLP-1 that is not semaglutide. FDA approved orforglipron on 1 April 2026 under NDA 220934 as a Type 1 New Molecular Entity, sponsored by Eli Lilly. Its approved indication is weight management only. A diabetes indication is not in the current label.
All four labels say the same thing about combining them: taking an oral GLP-1 alongside another GLP-1 receptor agonist is not recommended. Our full GLP-1 medication list covers the injectables in the same class.
Every semaglutide tablet, whether it is branded Rybelsus, Ozempic or Wegovy, comes with the same administration block in its prescribing information:
That last line is the one that reorganizes your day. Semaglutide is a peptide, and swallowing a peptide is normally pointless because your stomach digests it. The tablet works around that with an absorption enhancer that only works in a stomach that is empty and holding very little liquid. More water is not better here, which runs backwards from the hydration habits most people build on a weekly injection.
In practice that means no coffee for the first half hour of every morning. On a semaglutide tablet, coffee timing stops being a preference and becomes a label instruction.
The thirty-minute rule also applies to your other prescriptions. If you take levothyroxine, which has its own empty-stomach requirement, two medications are now competing for the same window. That is a question for your prescriber and pharmacist, not one to solve by guessing, and we cover it in GLP-1s and thyroid medication.
Foundayo's dosage section is startlingly short by comparison: take it once daily, with or without food, swallow tablets whole, no more than one per day. No empty-stomach requirement, no water limit, no waiting period, because a small molecule does not need an absorption enhancer to survive the stomach.
The trade-off shows up in the drug interactions section instead. Because orforglipron is metabolized through CYP3A4, its label sets rules that no semaglutide product has:
Orforglipron also delays gastric emptying, so its label carries the same caution every GLP-1 does about the absorption of other oral medicines taken alongside it.
The dose ladder runs 0.8 mg for at least 30 days, then 2.5 mg for at least 30 days, then 5.5 mg, with optional further steps to 9, 14.5 and 17.2 mg at intervals of at least 30 days based on response and tolerability. Which step you land on, and whether you move up at all, is a prescriber's decision.
These numbers come from the labels, and each one is a comparison against placebo inside one trial, not a comparison between the drugs.
Wegovy tablets 25 mg (Study 7 in the label, registered as OASIS 4, NCT05564117): after a 12-week escalation and a 52-week maintenance period, the 25 mg tablet group lost a mean 13.6% of body weight versus 2.4% on placebo. In that trial, 59.8% of the tablet group lost at least 10% of body weight compared with 14.4% on placebo. The trial randomized 307 people.
Foundayo (Trials 1 and 2 in the label, registered as ATTAIN-1 NCT05869903 and ATTAIN-2 NCT05872620). At week 72 in ATTAIN-1, which enrolled 3,127 adults without type 2 diabetes, mean weight change was -7.4% at 5.5 mg, -8.3% at 9 mg and -11.1% at 17.2 mg, against -2.1% for placebo. In ATTAIN-2, which enrolled 1,613 adults with type 2 diabetes, the same doses produced -5.1%, -7.0% and -9.6% against -2.5% for placebo. As with the injectables, the diabetes population lost less.
Rybelsus and Ozempic tablets are not approved for weight loss, so there is no weight-loss claim to quote from their labels.
If you want a straight answer on which oral GLP-1 works best, the honest one is that nobody has run the trial. A 2026 network meta-analysis in Obesity Science & Practice pooled nine randomized trials covering 5,766 participants on oral semaglutide, orforglipron, danuglipron and lotiglipron, and found high-dose oral semaglutide and high-dose orforglipron produced the largest reductions, around -11.6% and -11.8% respectively. Its own conclusion names the limitation: evidence certainty was low to moderate, and the lack of head-to-head comparisons constrains any comparative claim.
Foundayo's label lists the adverse reactions occurring in at least 5% of treated patients as nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, reflux, flatulence and hair loss. At 17.2 mg, nausea was reported by 35% versus 10% on placebo, vomiting 24% versus 4% and constipation 24% versus 9%. Across both trials, 8% of Foundayo-treated patients stopped because of adverse reactions against 3% on placebo, and most of those were gastrointestinal.
That is the same profile people describe on the injections, which is worth saying because "pill" reads as gentler than "shot" and the labels do not support that reading. Our guides to nausea and constipation apply equally on an oral GLP-1.
One oddity deserves a mention. Every GLP-1 in this class carries a boxed warning about thyroid C-cell tumors, and Foundayo does too, but its warning contains an unusual admission: orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents. The warning is retained because the human relevance of the rodent finding has not been determined. It remains contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
One item on the list is already being retired. On 4 June 2026, FDA's drug discontinuations database recorded all three Rybelsus strengths as "To Be Discontinued," the stated reason being discontinuation of manufacture, with a note that these products will be replaced by Ozempic tablets. The molecule is not going anywhere. The brand name and its milligram numbers are. If you are on Rybelsus 14 mg, the equivalent Ozempic tablet is 9 mg, and that renumbering is worth confirming with your pharmacist. Our Rybelsus guide covers the switch.
Is there an oral GLP-1 for weight loss? Yes, two of them. Wegovy tablets, at a 25 mg maintenance dose, and Foundayo (orforglipron), at doses up to 17.2 mg, are both FDA approved for weight management in adults with obesity or with overweight plus a weight-related condition. Rybelsus and Ozempic tablets are approved for type 2 diabetes, not weight loss.
Are oral GLP-1s as effective as the injections? Not proven either way, because these trials ran against placebo rather than against each other. The label figures for Wegovy tablets at 25 mg (-13.6% at 64 weeks) and Foundayo at 17.2 mg (-11.1% at 72 weeks) come from different trials with different designs and populations. Our oral versus injectable comparison walks through why lining them up does not work.
Do oral GLP-1s cause fewer side effects than the shots? The labels do not show that. Nausea, vomiting, diarrhea and constipation dominate the adverse reaction tables for the oral products just as they do for the injections, and the rates rise with dose.
Why do semaglutide tablets need an empty stomach but Foundayo does not? Semaglutide is a peptide and needs an absorption enhancer to survive being swallowed, and that enhancer only works with an empty stomach and very little water. Orforglipron is a small molecule that absorbs without one, which is why its label permits taking it with or without food.
Can I switch from my weekly injection to a pill? Only with a prescriber. The semaglutide labels include specific instructions for switching between tablets and from the injection to the tablets, and the milligram numbers do not carry over between products. Taking two GLP-1 receptor agonists at once is not recommended on any of the four labels.
This article reports what FDA labels and published trials say. It is not medical advice, and no dose here is a recommendation. Dosing, switching and stopping are decisions for your prescriber.